Editas halts lead CRISPR program after efficacy data underwhelm

Editas Medicine will put a wrap on its lead clinical program after reporting disappointing results from a Phase I/II trial.

The biotech, one of the first to try to use CRISPR gene editing tech to develop new drugs, said Thursday morning that only three of 14 patients responded to the therapy, known as EDIT-101. Execs will try to find a partner for the program, which is designed to treat an inherited form of blindness called CEP290-mediated LCA10.